INTEGRA LIFESCIENCES HOLDINGS CORPORATION (NASDAQ:IART) Files An 8-K Regulation FD DisclosureITEM 7.01 Regulation FD Disclosure
On December 11, 2017, Integra LifeSciences Holdings Corporation (the “Company”) issued a press release regarding the Company’s hosting of an Investor Day meeting with analysts and institutional investors in New York City on December 11, 2017, beginning at 8:00 a.m. EST, which is attached hereto as Exhibit 99.1. Members of the Company’s executive leadership team will discuss the Company’s financial performance and outlook, including:
|
Reaffirming 2017 financial guidance as provided on October 26, 2017, including: |
|
– |
Full-year 2017 revenue in the range of $1.165 billion to $1.175 billion, which includes about 4% organic growth |
|
– |
Full-year 2017 adjusted earnings per share in the range of $1.83 to $1.87; |
|
Providing 2018 preliminary revenue estimate in the range of $1.46 billion to $1.48 billion, which includes about 5% organic growth; |
|
Reaffirming 2018 adjusted earnings per share in the range of $2.25 to $2.35, consistent with preliminary estimates provided on October 26, 2017; and |
|
Establishing five-year financial targets of approximately $2 billion in revenue and an adjusted EBITDA margin range of 28% to 30%. |
The information furnished in this Item 7.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, unless the Company specifically states that the information is to be considered “filed” under the Exchange Act or incorporates it by reference into a filing under the Exchange Act or the Securities Act of 1933, as amended.
Item 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(d) Exhibits
INTEGRA LIFESCIENCES HOLDINGS CORP ExhibitEX-99.1 2 integrainvestordaypressrel.htm EXHIBIT 99.1 Exhibit Integra LifeSciences Hosts Investor Day 2017 New York CityPLAINSBORO,…To view the full exhibit click here
About INTEGRA LIFESCIENCES HOLDINGS CORPORATION (NASDAQ:IART)
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing and marketing of surgical implants and medical instruments. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery. Its segments include Specialty Surgical Solutions, which offers products, including specialty surgical instrumentation for a range of specialties. Its product category includes products and solutions for dural repair, precision tools and instruments, tissue ablation and neuro critical care, including product portfolios used in neurosurgery operation suites and critical care units, and Orthopedics and Tissue Technologies, which offers products of a combination of differentiated regenerative technology products for soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement hardware products for both upper extremities and lower extremities.
